Europe Facial Injectable Market Research Report- Forecast to 2027

Europe Facial Injectable Information, by types (Hyaluronic Acid, Collagen, Botulinum Toxin, Polymers and Particles, others) by application (facial surgery, facial uplift, others) by end users (hospitals, clinics, research and development facilities) - Forecast to 2027

ID: MRFR/MED/1896-CR | October 2016 | Region: Global | 100 pages

Please note that the assessment period of report has been updated from 2016-2021 to 2020-2027. Cordially fill the sample form for updated data.

Market Synopsis of Facial Injectable Market:


Market Scenario: Facial Injectable or also known as Dermal Fillers are products which help in a trending application known as bio-engineering or facial rejuvenation. As humans age the facial skin is bound to lose subcutaneous fat naturally, the skin is lured closer to the facial working muscles hence smile lines and wrinkles over the face become more visible.


Study Objectives of Facial Injectable Market:



  • To provide detailed analysis of the market structure along with forecast for the next 5 years of the various segments and sub-segments of the Facial Injectable market  

  • To provide insights about factors affecting the market growth

  • To analyze the Facial Injectable market based on various factors- price analysis, supply chain analysis, porters five force analysis etc.

  • To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries-Europe

  • To provide country level analysis of the market with respect to the current market size and future prospective

  • To provide country level analysis of the market for segments by type, by application, by end users and its sub-segments

  • To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market

  • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the Europe Facial Injectable market.


Intended Audience:



  • Facial Injectable manufacturers

  • Facial Injectable Suppliers

  • Pharmaceutical companies

  • Research and Development (R&D) Companies

  • Medical Research Laboratories

  • Academic Medical Institutes and Universities


Key Findings:



  • The Europe Facial Injectable market and is expected to reach $2,988.0 million by 2021.

  • Interferon’s segment holds the largest share in the market.

  • Europe holds the largest market share of the Facial Injectable market and is anticipated to grow at a CAGR of 13.2% by the end of forecast period 2016-2021.

  • Monoclonal Antibodies is expected to be fastest growing segment and are anticipated to grow at the rate of 4% during the forecast period.


Segments: Europe Facial Injectable market has been segmented on the basis of types which comprises of Hyaluronic Acid, Collagen, Botulinum Toxin, Polymers and Particles and others. On the basis of end users which consists of hospitals, clinics, research and development facilities and others. On the basis of application which consists of facial surgery, facial uplift and others.


Regional Analysis of Facial Injectable Market: Europe is the largest market for Facial Injectable. The European market for Facial Injectable is expected to grow at a CAGR of 13.5% and is expected to reach at US$ 2,988.0 Million by the end of the forecasted period. This is due to increasing approvals of facial inject-able products in emerging markets.


Key Players for Facial Injectable Market: Some Of The Key Players In This Market Are: Allergan Inc (Ireland), Merz Pharma (Germany), Ipsen (France), Valeant Pharmaceuticals (Canada), Galderma (Switzerland), Integra Lifesciences (Us), Tei Biosciences, Fibrogen (Finland), Ethicon (Us) And Others


The report for Europe Facial Injectable Market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions



1 REPORT PROLOGUE

2 INTRODUCTION

2.1 DEFINITION

2.1.1 DEFINITION OF FACIAL INJECTABLES

2.1.2 SPECIFICATIONS OF FACIAL INJECTABLES

2.1.3 CLASSIFICATION OF FACIAL INJECTABLES

2.1.4 MARKET SEGMENT BY REGIONS

2.2 SCOPE OF THE STUDY

2.2.1 RESEARCH OBJECTIVE

2.2.2 ASSUMPTIONS

2.2.3 LIMITATIONS

2.3 MARKET STRUCTURE

2.4. MARKET SEGMENTATION

3 RESEARCH METHODOLOGY

3.1 RESEARCH PROCESS

3.2 PRIMARY RESEARCH

3.3 SECONDARY RESEARCH

3.4 MARKET SIZE ESTIMATION

3.5 FORECAST MODEL

4 MARKET DYNAMICS

4.1 DRIVERS

4.2 RESTRAINTS

4.3 OPPORTUNITIES

5 EUROPE FACIAL INJECTABLESMARKET: BY TYPES (USD MILLION)

6.1 INTRODUCTION

6.2 HISTORIC MARKET GROWTH

6.3 MARKET SIZE (SUB SEGMENTS)

6.3.1 BOTULINUM TOXIN

6.3.2 HYALURONIC ACID

6.3.3 COLLAGEN

6.3.4 POLYMERS AND PARTICLES (PPFS)

6 EUROPE FACIAL INJECTABLESMARKET, BY REGION (USD MILLION)

6.1 INTRODUCTION

6.2 NORTH AMERICA

6.2.1 US

6.2.2 CANADA

6.3 EUROPE

6.3.1 WESTERN EUROPE

6.3.1.1 GERMANY

6.3.1.2 FRANCE

6.3.1.3 ITALY

6.3.1.4 SPAIN

6.3.1.5 UK

6.3.1.6 REST OF WESTERN EUROPE

6.3.2 EASTERN EUROPE

6.4 ASIA-PACIFIC

6.4.1 CHINA

6.4.2 INDIA

6.4.3 JAPAN

6.4.4 SOUTH EAST ASIA

7 EUROPE FACIAL INJECTABLESMARKET: COMPANY LANDSCAPE

7.1 INTRODUCTION

7.2 COMPANY SHARE ANALYSIS (%)

7.3 COMPETITIVE LANDSCAPE

7.3.1 PRODUCT LAUNCH/DEVELOPMENT

7.3.2 PARTNERSHIPS AND COLLABORATIONS

7.3.3 ACQUISITIONS

7.3.4 BUSINESS EXPANSION

8 COMPANY PROFILE

8.1 ALLERGAN

8.1.1 COMPANY OVERVIEW

8.1.2 PRODUCT/BUSINESS SEGMENT OVERVIEW

8.1.3 FINANCIAL UPDATES

8.1.4 KEY DEVELOPMENTS

8.2 LUMINERA DERM LTD

8.2.1 COMPANY OVERVIEW

8.2.2 PRODUCT/BUSINESS SEGMENT OVERVIEW

8.2.3 FINANCIAL UPDATES

8.2.4 KEY DEVELOPMENTS

8.3 MERZ PHARMA

8.3.1 COMPANY OVERVIEW

8.3.2 PRODUCT/BUSINESS SEGMENT OVERVIEW

8.3.3 FINANCIAL UPDATES

8.3.4 KEY DEVELOPMENTS

8.4 IPSEN

8.4.1 COMPANY OVERVIEW

8.4.2 PRODUCT/BUSINESS SEGMENT OVERVIEW

8.4.3 FINANCIAL UPDATES

8.4.4 KEY DEVELOPMENTS

8.5 ETHICON

8.5.1 COMPANY OVERVIEW

8.5.2 PRODUCT/BUSINESS SEGMENT OVERVIEW

8.5.3 FINANCIAL UPDATES

8.5.4 KEY DEVELOPMENTS

8.6 VALEANT PHARMACEUTICALS INTERNATIONAL

8.6.1 COMPANY OVERVIEW

8.6.2 PRODUCT/BUSINESS SEGMENT OVERVIEW

8.6.3 FINANCIAL UPDATES

8.6.4 KEY DEVELOPMENTS

8.7 GALDERMA

8.7.1 COMPANY OVERVIEW

8.7.2 PRODUCT/BUSINESS SEGMENT OVERVIEW

8.7.3 FINANCIAL UPDATES

8.7.4 KEY DEVELOPMENTS

8.8 FIBROGEN

8.8.1 COMPANY OVERVIEW

8.8.2 PRODUCT/BUSINESS SEGMENT OVERVIEW

8.8.3 FINANCIAL UPDATES

8.8.4 KEY DEVELOPMENTS

8.9 TEI BIOSCIENCES

8.9.1 COMPANY OVERVIEW

8.9.2 PRODUCT/BUSINESS SEGMENT OVERVIEW

8.9.3 FINANCIAL UPDATES

8.9.4 KEY DEVELOPMENTS

9 APPENDIX